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CTLA-4: From conflict to clinic
CTLA-4 was first identified in 1991 as a second receptor for the T cell 
costimulation ligand B7. Uncertainties about its biological function plagued 
the early years after its discovery until 1995, when it was confirmed to be an 
inhibitor of T cell responses. CTLA-4 has since scored in the clinic as a target 
for antitumor therapy and as a soluble inhibitor of autoimmunity.
By the late 1980s, it was clear that naive 
T cells require two signals through two 
different receptors to spark to life. Tick-
ling the T cell receptors (TCRs) alone 
with antigenic ligands makes the cells 
anergic. But a second signal from the B7 
ligand on antigen-presenting cells (APCs) 
to the CD28 coreceptor goads T cells 
into action (1). As researchers pursued 
the mechanism of B7-CD28–mediated 
T cell costimulation, another T cell sur-
face molecule was generating interest 
due to its homology with CD28.
Another T cell switch…
In 1987, researchers hunting for cyto-
toxic cell surface molecules isolated a 
cDNA from activated CD8+ T cells 
and called it cytotoxic T cell antigen 
(CTLA)-4 (2). Genetic studies provided 
a clue that connected CTLA-4 to T 
cell costimulation: CTLA-4 and CD28 
both mapped to the same chromosomal 
neighborhood and shared a high degree 
of sequence similarity (3).
This information caught the atten-
tion of Jeffrey Ledbetter and Peter 
Linsley at the Bristol-Myers Squibb 
Research Institute (Seattle, WA). At 
the time, their group was studying 
B7-CD28 interactions using a soluble 
version of CD28 that lacked trans-
membrane and intracellular domains. 
The soluble CD28 protein worked 
just as well as the cell-attached version 
in binding B7 (4). So when CTLA-4 
appeared on the radar, Linsley con-
structed a soluble CTLA-4 protein. The 
team hedged their bets on the similarities 
between CTLA-4 and CD28 and tested 
whether CTLA-4 also bound B7.
Soluble CTLA-4 turned out to bind 
B7 with 20-fold higher avidity than the 
soluble CD28 protein, establishing 
CTLA-4 as a second receptor for B7. 
The group published these results in The 
Journal of Experimental Medicine in 1991 
(5). It now seemed that CTLA-4 was a 
third switch in what was previously 
thought to be a two-switch circuit for T 
cell activation. But whether it promoted 
or jammed the circuit was a contentious 
issue for several more years.
...but on or off?
The debate arose because in vitro assays 
of costimulation-dependent T cell 
proliferation offered multiple interpre-
tations. T cells normally proliferate in 
vitro when cultured with B7-express-
ing APCs. But when soluble CTLA-4 
was added to the mix, this proliferation 
was strongly inhibited (5).
One interpretation of this finding 
was that the soluble CTLA-4 blocked 
the binding of B7 to the CTLA-4 on 
the T cells. In this model, the T cell 
CTLA-4 was needed for proliferation, 
along with CD28. This conclusion was 
supported when the group showed 
that antibodies to CTLA-4 enhanced 
CD28-stimulated proliferation (6).
A second interpretation, however, 
was that soluble CTLA-4 might block 
proliferation by gumming up B7’s 
in  ter  action with CD28. And the CTLA-4 
antibody might enhance proliferation 
not because it stimulates CLTA-4’s 
proliferative power, but because it blocks 
CTLA-4’s negative signal.
This alternative role for CTLA-4 was 
supported by the work of James Allison 
and his team at the University of Califor-
nia (Berkeley, CA), which was also pub-
lished in the JEM (7). This group studied 
cross-talk among TCR, CD28, and 
CTLA-4 by cross-linking these receptors. 
T cells proliferated when the TCR was 
linked to CD28, but not with CTLA-4. 
T cell proliferation was greatly reduced 
when all three receptors were cross-
linked simultaneously, suggesting that 
CTLA-4 inhibits CD28 costimulation.
The generation of CTLA-4 knock-
out mice finally put the conflict to rest. 
These animals develop a fatal T cell 
proliferative disorder, as their T cells 
lack the brakes to hold them in check 
(8). CTLA-4 was thus established as a 
negative regulator of T cell function 
and proliferation.
CTLA-4 in the clinic
One benefit of enhancing T cell re-
sponses via CTLA-4 blockade is the 
strengthening of antitumor immunity. 
Allison’s team found that tumor-trans-
planted mice injected with antibodies 
that block CTLA-4 activity rejected 
several different types of tumors and had 
long-lasting antitumor immunity (9). 
Human anti-CTLA-4 mAbs are now in 
phase III clinical trials against melanoma 
and renal carcinomas. CTLA-4 has also 
been called into service to turn off 
dangerous immune responses. The T 
cell–inhibiting soluble CTLA-4 origi-
nally defined by Linsley and Ledbetter is 
now used to treat autoimmune diseases 
such as rheumatoid arthritis.
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